Laser therapy extends glioblastoma survival when more tumor removed, study finds

When Eric Leuthardt performs brain surgery at Washington University School of Medicine, he does not open the skull. Instead, he drills a hole the width of a pencil, threads a robotically guided laser through it, and lets heat do the work. For patients with glioblastoma—the most aggressive form of brain cancer—this approach has begun to reshape what survival looks like.

Glioblastoma has long meant a grim calculus: open-skull surgery, chemotherapy, radiation, and roughly eighteen months of life. The disease kills fast and indiscriminately. But over the past fifteen years, neurosurgeons have been experimenting with an alternative. Laser interstitial thermal therapy, or LITT, targets tumors that are either impossible to reach through traditional surgery or have returned after initial treatment. A real-time MRI guides the laser probe through the brain's architecture, avoiding healthy tissue, until it reaches the tumor and burns it away from the inside. The tool, called NeuroBlate, received FDA clearance in 2009. Leuthardt performed the nation's first laser treatment for a brain metastasis at Barnes-Jewish Hospital in 2010.

Now a major analysis published in the Journal of Clinical Oncology offers concrete evidence of what this procedure can accomplish. Researchers at WashU Medicine analyzed outcomes for 787 brain tumor patients treated across 25 centers nationwide. The findings are striking: glioblastoma patients who had at least 91 percent of their tumor destroyed by the laser survived an average of 2.1 years from diagnosis—a full six months longer than the standard open-surgery survival rate of 1.5 years. For people facing a terminal diagnosis, those months matter. They mean time with family. Time to plan. Time to live.

But the study revealed something else equally important: timing is everything. Patients with brain metastases—cancers that have spread to the brain from elsewhere in the body—fared better when treated early, when tumors were still small, rather than waiting through multiple imaging cycles to confirm growth. This challenges a common clinical practice of watchful waiting, the idea that doctors should observe and delay intervention until tumor progression is certain. The data suggests the opposite. Smaller tumors respond better. Earlier treatment saves lives.

The procedure itself transforms the patient experience. Traditional brain surgery means removing part of the skull, weeks of recovery, intensive care stays, and the risk of complications. LITT requires only a single stitch closing a millimeter-wide incision. Most patients go home within 32 hours. They avoid intensive care. They recover quickly enough to return to their families almost immediately. The laser also reduced the need for anti-seizure medication compared to before surgery—a meaningful improvement in daily quality of life for people already managing a devastating diagnosis.

Leuthardt and his team, including physician-scientist Albert Kim, emphasize that this is not a replacement for traditional surgery in all cases. Rather, it is a tool that expands options for patients who have few. For those with inoperable tumors or recurrent disease, for those whose location or condition makes open surgery too risky, the laser offers something previously unavailable: a low-risk procedure that extends survival and preserves the ability to go home. The study's data now gives clinicians concrete benchmarks—how much tumor needs to be removed, when treatment should occur—to identify which patients will benefit most. As Leuthardt puts it, the framework for handling brain tumors is shifting. When a patient hears they have months to live, knowing there is a procedure that might add years, and that they can recover at home in a day, changes everything.